Island Labs receives NHP approval for Stemcelex

Island Labs, a leader in natural dermatological products, has become the first company in Health Canada's history to receive Natural Health Product (NHP) approval.

In the United States and Canada alone there are over 50 million men and women experiencing premature thinning or hair loss. Stemcelex is a patented (PCT filed) product that has demonstrated hair growth for men and women on all areas of the scalp, including areas affected by androgenic alopecia (pattern baldness). Stemcelex naturally stimulates the population of stem cells within the hair follicle. Over thirty years in development, the product is safe and has shown to produce no adverse side effects.

Island Labs is also pleased to announce that Lorne Meikle has been appointed board chair at Island Labs. He will direct the global licensing and commercialization of Stemcelex. "Stemcelex research indicates that this innovative new product offers significant hair growth improvement over currently marketed products," Meikle said. Meikle was a member of senior management teams at industry leaders: Glaxo Canada, Smith Kline and French, Ortho-McNeil and Connaught Laboratories.

Having served as CEO for nine biotechnology companies, Meikle is currently president and CEO of Management Dynamics Ltd., a biotechnology and water resources firm; LOB Ordeins Inc., a human therapeutics delivery company and CEO of Neuroimage Inc. He is also chairman and director of Quest PharmaTech Inc. (TSXV-QPT).

Meikle has more than four decades of experience in executive management in health-care and joins Island Labs in their commitment to enhancing the quality of life by developing and delivering safe and effective dermatological products.